Prof. Dr. Ersin Özaslan
Medical Oncology- 2016 – Erciyes Universiteit, Faculteit Geneeskunde
Specialisatie Medische Oncologie - 2012 – Erciyes Universiteit, Faculteit Geneeskunde
Specialisatie Interne Geneeskunde - 2007 – Universiteit van Istanbul, Faculteit Geneeskunde
Arts (M.D.)
Prof. Dr. Ersin Özaslan
Medical Oncology- 2018 – Heden – Acıbadem Gezondheidszorg Groep
Specialist Medische Oncologie - 2016 – 2018 – Kayseri Opleidings- en Onderzoeksziekenhuis
Afdeling Medische Oncologie
Prof. Dr. Ersin Özaslan
Medical Oncology- Efficacy and safety of cetuximab plus FOLFOX in second-line and third-line therapy in metastatic colorectal cancer
- Is sunitinib-induced hypothyroidism a predictive clinical marker for better response in metastatic renal cell carcinoma patients?
- Psychological distress and loneliness in caregiver of advanced oncological inpatients
- Evaluation of the concordance between the stage of the disease and Ki-67 proliferation index in gastroenteropancreatic neuroendocrine tumors
- Hepatic steatosis is associated with higher incidence of liver metastasis in patients with metastatic breast cancer
- Predictive significance of VEGF and HIF-1α expression in patients with metastatic colorectal cancer receiving chemotherapy combinations with bevacizumab
- Predicting the role of the pretreatment neutrophil to lymphocyte ratio in the survival of early triple-negative breast cancer patients
- Is late recurrence a predictive clinical marker for better sunitinib response in metastatic renal cell carcinoma patients?
- Positive effects of oral β-glucan on mucositis and leukopenia in colorectal cancer patients receiving adjuvant FOLFOX-4 combination chemotherapy
- Lack of prognostic value of mean corpuscular volume with capecitabine therapy in metastatic breast cancer